



# Osteochondral Allograft (OCA) Kit



## Comparing Cartilage Defect Repair Treatment Alternatives

	Defect Characteristics	Tissue Characteristics	Procedure Characteristics
<b>Autologous Chondrocyte Implantation (ACI)</b>	Chondral femoral defects; routinely 5 to 10 cm <sup>2</sup>	Adult autologous chondrocytes	One or two-stage surgical procedure, fixation from scaffold or cover subsequent reoperations common <sup>5</sup>
<b>Bone Marrow Stimulation*</b>	Chondral; limited treatment area < 2 cm <sup>2</sup>	No tissue implanted, fibrous repair tissue <sup>6-7</sup>	Single stage surgery, simple technique, may be done arthroscopically
<b>Osteochondral Autograft</b>	Osteochondral; limited treatment area < 2 cm <sup>2</sup>	Adult autologous tissue from non-weight bearing surface	Single stage complex procedure, perpendicular access to defect required, donor site morbidity
<b>Osteochondral Allograft</b>	Osteochondral; large defects > 2 cm <sup>2</sup>	Adult allograft tissue, risk of disease transmission, typical wait period for graft availability	Single stage complex procedure, perpendicular access to defect required
<b>Micronized Cartilage Matrix (BioCartilage®)</b>	Chondral; limited treatment area < 2 cm <sup>2</sup>	Dehydrated, micronized adult cartilage	Single stage surgery, augment to bone marrow stimulation procedures, no published clinical evidence
<b>OCA Kit</b>	Osteochondral defects up to 5 cm <sup>2</sup>	Juvenile (≤ 13 yrs) hyaline cartilage	Single stage surgery, simple technique with fibrin fixation, may be done arthroscopically, used in multiple joints including knee (patellofemoral & condyle)

\* e.g., debridement, microfracture, chondroplasty, subchondral drilling, etc.

# ADVANCING THE SCIENCE OF CARTILAGE REPAIR




## OSTEOCHONDRAL ALLOGRAFT (OCA) KIT

Zimmer Biomet's OCA Kit is an osteochondral allograft containing fresh young allograft cartilage and cancellous chips for treatment and repair of osteochondral deficiencies that can occur in multiple anatomic locations, such as the knee, hip, ankle and upper extremities. It allows for a single-stage procedure with fibrin fixation, eliminating the need for harvesting autograft or a periosteal flap - thereby reducing donor site morbidity and saving time in the OR.

The kit offers an Early Intervention option that can limit the need for further surgical intervention and potentially divert the progression of these lesions.

### Advantages:

- Includes young allograft cartilage, which contains 10x greater chondrocyte density than adult tissue and does not elicit an allogeneic immune response<sup>1-3</sup>
- Implanted in a single-stage procedure with fibrin fixation - no need to harvest a periosteal flap, tissue or cells from areas of undamaged cartilage
- Survivorship at 5 years 85% in knee and 89% in ankle<sup>4,5</sup>
- Significantly reduce pain and improve function for at least 5 years<sup>4,6</sup>



## Cartilage Injury and Treatment

There are over 600,000 cartilage procedures performed in the US annually.<sup>7</sup> Some of the clinical challenges with these procedures are the variation in size and severity of the lesions and the fact that spontaneous cartilage repair rarely happens due to no blood vessels and low cell density in cartilage.<sup>8</sup>

The OCA Kit cartilage graft consists of young living articular cartilage, which displays beneficial properties similar to those of articular cartilage found in young, healthy joints. The modular graft makes it possible to address deficiencies of various sizes and shapes.

## Young Allograft Cartilage Tissue

In comparison with using adult articular cartilage, which has limited capacity for self-repair<sup>9</sup>, young living articular cartilage contains 10x greater chondrocyte density than adult tissue and does not elicit an allogeneic immune response.<sup>1-3</sup>


### Comparison of Young versus Adult Bovine Cartilage<sup>9</sup>

A study comparing young versus adult bovine cartilage demonstrated:

- A. Juvenile bovine cartilage has significantly higher cell density than adult cartilage ( $p < 0.05$ )
- B. Juvenile bovine chondrocytes have significantly higher proliferation rate than adult chondrocytes (Day 3,  $p < 0.01$ )
- C. Juvenile chondrocytes synthesize significantly greater amount of glycosaminoglycan (GAG)\* than adult chondrocytes ( $p < 0.05$ )



### Young versus adult bovine cartilage\*\*



\*A naturally occurring carbohydrate found in cartilage and is used as a biomarker that indicates chondrocytes' matrix generating potential.

\*\* Human cartilage may not respond the same as bovine cartilage.

# CLINICAL EXPERIENCE

## Zimmer Biomet's Young Allograft Cartilage


Zimmer Biomet's young allograft cartilage has been used to treat focal defects in a wide range of anatomical applications, including:

- Knee (i.e., condyle, trochlea, patella, tibial plateau)
- Foot and ankle (i.e., talus, MPJ)
- Elbow
- Shoulder (i.e., humeral head, glenoid)
- Hip (i.e., acetabulum, femoral head)

Zimmer Biomet Longitudinal studies in the knee and ankle demonstrated 85% and 89% graft survivorship at 5 years respectively.<sup>4,5</sup>

Clinical trials on Zimmer Biomet's young allograft cartilage in both the ankle and knee demonstrate significant improvement in patient reports of pain, function and activity scores (KOOS, AOFAS, FAAM, VAS pain scales).<sup>6,11,12</sup>


### Patient reported KOOS sub scores of independent study utilizing Zimmer Biomet young allograft cartilage to treat lesion in the knee<sup>6</sup>



Outcome scores in 25 knee patients 24 months following implant of Zimmer Biomet's young allograft cartilage. Significant improvement over baseline is seen for pain, symptoms, functions and sports ( $p < 0.05$ ).



## SURVIVORSHIP AT 5 YEARS



MRI of 35 year old male with medial talus lesion, preoperative (left) and 6 months after surgery (right).

## References

1. Adkisson, H. D., *et al.* The potential of human allogenic juvenile chondrocytes for restoration of articular cartilage. *American Journal of Sports Medicine.* 38(7):1324-33, 2010.
2. Adkisson, H. D., *et al.* Immune evasion by neocartilage-derived chondrocytes: Implications for biologic repair of joint articular cartilage. *Stem Cell Research.* 4:57-68, 2010.
3. Feder, J., *et al.* The Promise of Chondral Repair Using Neocartilage. In *Tissue Engineering in Musculoskeletal Clinical Practice* (eds. L. Sandell & A. Grodzinsky), American Academy of Orthopaedic Surgeons, Rosemont, IL, pp.219-226.
4. Data on file Zimmer Biomet. Post-Market, Longitudinal Data Collection Study of DeNovo® NT for Articular Cartilage Defects of the Knee, protocol number CSU2010-22B.
5. Data on file Zimmer Biomet. Post-Market, Longitudinal Data Collection Study of Articular Cartilage Lesions in the Ankle Treated with DeNovo NT Natural Tissue Graft, protocol number CSU2010-21B. Nov 13, 2017.
6. Farr, J., *et al.* Clinical, Radiographic and Histological Outcomes following Cartilage Repair with Particulated Juvenile Articular Cartilage: A 2-Year Prospective Study. *American Journal of Sports Medicine.* 42(6):1417-25, 2014.
7. DRG Report. Medtech360 Sports Medicine Devices. Market Analysis. US. 2018.
8. Mandelbaum BR, *et al.* Articular cartilage lesions of the knee. *American Journal of Sports Medicine.* 26:853-861, 1998.
9. Liu, H., *et al.* Enhanced Tissue Regeneration Potential of Juvenile Articular Cartilage. *American Journal of Sports Medicine.* Nov;41(11):2658-67, 2013.
10. Farr, J., *et al.* Chondral Defect Repair with Particulated Juvenile Cartilage Allograft. *Cartilage.* Oct 2(4):346-353, 2011.
11. Coetzee, J. C., *et al.* Treatment of Osteochondral Lesions of the Talus With Particulated Juvenile Cartilage. *Foot & Ankle International.* Sep;34(9):1205-11, 2013.

All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.

This material is intended for health care professionals. Distribution to any other recipient is prohibited.

For indications, contraindications, warnings, precautions, potential adverse effects and patient counselling information, see the package insert or contact your local representative; visit [www.zimmerbiomet.com](http://www.zimmerbiomet.com) for additional product information.

©2021 Zimmer Biomet



### Authorized Representative

Zimmer GmbH  
Sulzerallee 8  
8404 Winterthur  
Switzerland



### Legal Manufacturer

Zimmer, Inc.  
1800 West Center Street  
Warsaw, IN 46801-0708  
USA



**ZIMMER BIOMET**

Your progress. Our promise.®

33371-US-en-Issue Date 2021-03-25

[www.zimmerbiomet.com](http://www.zimmerbiomet.com)

2797